| 注册
首页|期刊导航|中国医学创新|慢性肾脏病患者应用达格列净治疗的效果分析

慢性肾脏病患者应用达格列净治疗的效果分析

于娟娟

中国医学创新2025,Vol.22Issue(34):15-18,4.
中国医学创新2025,Vol.22Issue(34):15-18,4.DOI:10.3969/j.issn.1674-4985.2025.34.004

慢性肾脏病患者应用达格列净治疗的效果分析

Analysis of Therapeutic Effect of Dapagliflozin in Patients with Chronic Kidney Disease

于娟娟1

作者信息

  • 1. 六盘水市人民医院肾内科 贵州 六盘水 553000
  • 折叠

摘要

Abstract

Objective:To analyze the therapeutic effect of Dapagliflozin on patients with chronic kidney disease.Method:A total of 72 patients with chronic kidney disease in Liupanshui People's Hospital from March 2021 to June 2024 were included in the study.The patients were divided into the control group(36 cases)and the study group(36 cases)by random number table grouping.The control group was treated with conventional medical treatment,while the study group was treated with Dapagliflozin based on the control group,both groups continued the medication for 3 months.The clinical efficacy,renal function[Cr,glomerular filtration rate(GFR),BUN,albumin(ALB),24 h urinary protein quantitative],cardiac function indexes[left ventricular mass index(LVMI),left atrial volume index(LAVI),the ratio of the mitral valve blood flow velocity(E)in the early left ventricular diastolic period to the mitral valve annular movement velocity(e')in the early left ventricular diastolic period(E/e'),left ventricular ejection fraction(LVEF)],drug adverse reactions were compared between the two groups.Result:The total effective rate of the study group was higher than that of the control group(P<0.05).Before treatment,the differences of renal function indicators were not statistically significant(P>0.05),after treatment,Cr,BUN,24 h urinary protein quantitative in the study group were lower than those in the control group,GFR,ALB in the study group were higher than those in the control group(P<0.05);before treatment,there were no statistically significant differences in cardiac function indicators between the two groups(P>0.05),after treatment,LVMI,LAVI,E/e'in the study group were lower than those in the control group,LVEF in the study group was higher than that in the control group(P<0.05).There was no significant difference in drug adverse reactions between the two groups(P>0.05).Conclusion:The use of Dapagliflozin in the treatment of chronic kidney disease can reduce proteinuria,improve cardiac function and delay renal progression.

关键词

慢性肾脏病/达格列净/治疗效果/肾功能

Key words

Chronic kidney disease/Dapagliflozin/Therapeutic effect/Renal function

引用本文复制引用

于娟娟..慢性肾脏病患者应用达格列净治疗的效果分析[J].中国医学创新,2025,22(34):15-18,4.

中国医学创新

1674-4985

访问量0
|
下载量0
段落导航相关论文